DIFFUSE LARGE B CELL LYMPHOMA

This study tested whether adding polatuzumab vedotin to standard chemotherapy (R-GEMOX) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 270 adults took part. The goal was to see if the combination improves survival and controls the cancer bet…

This early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study had two parts: one to determine t…

This study tested adding lenalidomide to standard chemotherapy (RICE) for people with diffuse large B-cell lymphoma that returned after initial treatment. The goal was to see if the combination could shrink tumors more effectively, allowing more patients to receive a stem cell tr…

This study tested whether adding lenalidomide to standard chemotherapy (R-CHOP) helps people with a fast-growing type of lymphoma called diffuse large B-cell lymphoma. 60 adults with medium-to-high risk disease took part. The goal was to see if the combination improves how long p…

This study tested whether adding an oral drug called tucidinostat to standard chemotherapy (R-CHOP) helps people with a fast-growing type of lymphoma called double-expressor DLBCL. The trial involved 423 newly diagnosed adults and measured how long they lived without the cancer g…

This study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant could help keep lymphoma from coming back. It included 82 adults with Hodgkin or non-Hodgkin lymphoma that had returned or not responded to prior treatment. The main goal was to see…

This study tested a new way of giving chemotherapy called dose-adjusted EPOCH-R in children with certain B-cell cancers (DLBCL, PMBCL, or PTLD). The goal was to see if it is safe and could improve cure rates while reducing side effects, as it has in adults. Only 4 children took p…

This early-phase study tested a new combination of drugs (romidepsin plus standard chemotherapy) in 21 patients with peripheral T-cell or diffuse large B-cell lymphoma. The main goal was to find the safest dose and understand side effects. Researchers hope this combo might work b…

This study tested a new radiation therapy schedule for people with B-cell lymphoma that has come back or not responded to treatment. Participants received radiation once a week for five weeks before their CAR T-cell therapy. The goal was to see if this schedule makes radiation ea…

This study looked at how safe and effective a combination of two drugs (tafasitamab and lenalidomide) is for people with a type of blood cancer called diffuse large B-cell lymphoma that has returned or stopped responding to treatment. The study focused on including patients from …

This early-stage study tested a new type of CAR-T cell therapy (C-CAR066) in 7 adults with diffuse large B-cell lymphoma whose cancer returned or didn't respond after a prior CAR-T treatment. The therapy targets a protein called CD20 on cancer cells. The main goals were to check …

This study tested a new drug (BGB-10188) alone or with other drugs in 97 people with certain blood cancers or advanced solid tumors. The goal was to find the safest and most effective dose. However, the best dose could not be determined for all groups because not enough data was …

This early-phase study tested a new treatment called BZ019 for adults with B-cell lymphoma that came back or didn't respond to standard therapy. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals were to check safety and see if the tr…

This study tested two different drug combinations for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who cannot receive standard chemotherapy. The goal was to see which combination works better and is safer. 129 patients took part, and the results…

This study tested different combinations of immune-suppressing drugs to prevent graft-versus-host disease (GVHD) in 174 patients with blood cancers who received a stem cell transplant from an unrelated donor. The goal was to find the most effective approach to reduce severe GVHD,…

This study tested the drug chidamide as a maintenance therapy for 30 people with hepatitis B virus (HBV)-positive diffuse large B-cell lymphoma who had already achieved complete remission after chemotherapy. The goal was to see if chidamide could help keep the cancer from returni…

This early-stage study tested the safety and highest tolerable dose of a new, genetically modified immune cell therapy called PRGN-3007 UltraCAR-T in adults with advanced blood cancers and triple-negative breast cancer. The main goal was to see how much of the treatment patients …

This study followed 60 adults with diffuse large B-cell lymphoma who were scheduled to receive a standard CAR T-cell therapy called axi-cel. Researchers measured changes in memory, attention, thinking skills, and quality of life using questionnaires and tests. The goal was to und…

This study looked at how levels of circulating tumor DNA (ctDNA) change in the hours after the first dose of chemotherapy for diffuse large B-cell lymphoma. Researchers wanted to find the best time to take blood samples for follow-up testing. The study involved 24 adults with thi…

This study looked at how genetic differences affect the body's ability to clear high-dose methotrexate in patients with diffuse large B-cell lymphoma. Researchers analyzed DNA from 20 adult patients to find specific gene variations linked to slower drug removal. The goal is to be…

This study looked at 60 people with a type of blood cancer called diffuse large B-cell lymphoma. Researchers used advanced techniques to create a detailed map of the cancer cells and immune cells in the body. The goal was to find markers that could help track how the disease chan…